000028 国药一致
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入17,823,410-2.57%73,415,85874,378,49475,477,48573,443,137
减:营业总成本17,432,136-2.51%71,812,83073,017,47573,277,09771,309,688
    其中:营业成本16,048,355-2.15%65,575,39166,129,20966,425,42664,516,926
               财务费用34,309-10.31%182,960239,424204,535189,514
               资产减值损失(1,352)-24.52%(290,177)(994,532)(17,577)(71,588)
公允价值变动收益----3,129(20,675)(15,161)28,871
投资收益57,983-27.08%217,607241,793237,029139,131
    其中:对联营企业和合营企业的投资收益70,130-30.02%315,684369,703315,446298,527
营业利润376,587-14.24%1,512,829573,4782,467,4252,306,069
利润总额376,861-14.02%1,509,020575,4692,473,2272,311,070
减:所得税费用71,700-20.90%380,672338,466514,739539,332
净利润305,161-12.23%1,128,349237,0041,958,4871,771,738
减:非控股权益17,698-10.06%(7,578)(405,490)359,231285,030
股东净利润287,463-12.36%1,135,927642,4931,599,2561,486,708

市场价值指针
每股收益 (元) *0.520-11.86%2.0401.1502.8702.670
每股派息 (元) *----0.6160.3660.6800.800
每股净资产 (元) *33.9545.00%33.43731.74731.29037.666
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容